Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $96.0 million.

  • Taysha Gene Therapies' Total Non-Current Liabilities rose 10403.22% to $96.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.0 million, marking a year-over-year increase of 10403.22%. This contributed to the annual value of $87.5 million for FY2024, which is 902.86% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Total Non-Current Liabilities of $96.0 million as of Q3 2025, which was up 10403.22% from $83.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Total Non-Current Liabilities registered a high of $241.1 million during Q3 2023, and its lowest value of $47.0 million during Q3 2024.
  • Moreover, its 4-year median value for Total Non-Current Liabilities was $96.2 million (2023), whereas its average is $100.3 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Total Non-Current Liabilities surged by 15003.22% in 2023, and later plummeted by 8048.3% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Total Non-Current Liabilities (Quarter) stood at $121.2 million in 2022, then decreased by 20.61% to $96.2 million in 2023, then decreased by 9.03% to $87.5 million in 2024, then rose by 9.66% to $96.0 million in 2025.
  • Its last three reported values are $96.0 million in Q3 2025, $83.2 million for Q2 2025, and $82.1 million during Q1 2025.